[ad_1]
In a statement, the lab reveals it the vaccine prevents 70 percent of people from developing the disease caused by the new coronavirus, according to the interim results of the phase 3 tests that proved it efficacy resulted from the combination of two dosing regimens: one was 90% effective and the other 62%.
These are interim results of large-scale clinical trials developed in the UK and Brazil, says AstraZeneca. But in relation to the data already available, this vaccine has a lower efficacy rate than those of Pfizer / BioNTech or Moderna, which exceed 90 percent.
“The results of an interim analysis of AZD1222 clinical trials showed that the vaccine was highly effective in preventing Covid-19, its primary target, and there were no hospitalizations or severe cases of the disease in participants who received the vaccine. A total of 131 cases of Covid-19 were recorded in the provisional analysis “, read in the AstraZeneca statement.
Researchers involved in the production of this vaccine also pointed out that the vaccine “It is effective in preventing many people from getting sick and has been shown to work well in different age groups.”
The pharmaceutical company adds that efficacy can even reach 90 percent “under one dosage regimen”.
“The efficacy and safety of this vaccine confirms that it will be highly effective against Covid-19 and will have an immediate impact in this health emergency,” Pascal Soriot, CEO of AstraZeneca, said in the statement.
More than 20,000 volunteers were involved, half in the UK and half in Brazil. Among those who received two doses of the vaccine, there were 30 cases of Covid-19 and 101 cases in people who received a sham injection.
When volunteers received two “high” doses, the protection was 62%, but increased to 90% when people received a lower “dose” followed by a high dose. It is not yet clear, however, why this difference in effectiveness.
According to the BBC andthese results may be a triumph but also a disappointment after the results announced by the pharmaceutical companies Pfizer and Moderna proved superior. However, the Oxford vaccine is much cheaper, easier to store and to reach in all corners of the world than the other two, which could mean it will play a significant role in fighting the pandemic if approved by regulators, the UK broadcaster said.
Therefore, although the AstraZeneca vaccine efficacy rate is lower, it is expected that it will play a significant role in fighting the pandemic if approved by regulators.
Remember that Researchers at Oxford University went through the normal process of developing a vaccine, which would take a decade in just ten months.
Preliminary results now released by biopharmaceuticals have not yet been reviewed by peers or published in any scientific journals, which is expected to happen as soon as full clinical trial results are available. Process which, according to AstraZeneca, is already underway.
.
[ad_2]
Source link
